Medtronic has entered into a partnership agreement with Viz.ai to accelerate the adoption of artificial intelligence software for stroke prevention and treatment in US centres. A press release from Medtronic announced the collaboration, describing Viz.ai as “the emerging leader in applied artificial intelligence in stroke care”.
The statement outlines how Viz.ai’s technology uses artificial intelligence to identify suspected large vessel occlusion (LVO) strokes and automatically notify specialists. The software connects to hospital computed tomography (CT) scanners and alerts stroke specialists within minutes that a suspected LVO stroke has been identified, sending the radiological images directly to their smartphones where they can be viewed. It says that Viz.ai enables a physician to provide the patient with the treatment they need as quickly as possible.
Through the agreement, Medtronic will distribute Viz.ai’s existing LVO detection and triage software services, which are currently permitted for marketing in the USA. The release describes it as the first clinical decision support software designed to analyse CT results that may notify providers of a potential stroke in their patients that was cleared by the US. Food and Drug Administration (FDA). The technology is available in >200 hospitals, and Medtronic says the goal is to make Viz.ai available to every stroke centre in the country.
Medtronic produces the Solitaire Platinum revascularisation device, which it describes in the press release as “a unique stent that retrieves clots from occluded blood vessels in the brain for patients experiencing acute ischaemic stroke (AIS) due to an LVO”.